title: Cytogenetic guidelines for fragile X studies tested in routine practice.
abstract: Several organizations have proposed guidelines for fra(X) studies on peripheral blood lymphocytes. To evaluate these guidelines, we reviewed 1,033 consecutive specimens referred for fra(X) analysis. Each specimen was cultured with medium 199 and RPMI 1640 with 5-fluorodeoxyuridine or excess thymidine. The karyotype and expression of fra(X) were established from 20 GTL- or QFQ-banded cells and by screening of up to 130 more banded cells. We found anomalies other than fra(X) in 37 (3.6%) of the patients. We found 4% or more fra(X) cells in 38 (3.7%) cases from 36 unrelated families, including 33 (3.9%) of 850 males and 5 (2.7%) of 183 females. Another 4 females had 1 to 3% fra(X) cells. Six specimens were fra(X)-positive in only one stress system, and 32 were positive in 2 systems. To find the first 2 fra(X) cells in males, we needed to study up to 36 cells in 31 cases, 50 in one case, and 57 in another. To find the first 2 fra(X) cells in females, we needed to study up to 17 cells in 4 cases and 57 in another. A strong family history of fra(X) occurred in 5 patients, and each one was fra(X)-positive. Some manifestations of the fragile X syndrome occurred in 507 cases, 17 (3%) of which were fra(X)-positive. Abnormalities considered unlikely to be the fragile X syndrome occurred in 103 cases, 3 (3%) of which were fra(X)-positive. Use of chromosome breakage and fra(3)(p14) as quality control indicators of the fra(X) stress systems was found to be unreliable.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Cytogenetics Laboratory, Mayo Clinic, Rochester, Minnesota 55905.
authors: G W
authors: GW
authors: Dewald
authors: D D
authors: DD
authors: Buckley
authors: J L
authors: JL
authors: Spurbeck
authors: S M
authors: SM
authors: Jalal
mesh_terms: D000293:Adolescent; D000328:Adult; D002452:Cell Count; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D003470:Culture Media; D003582:Cytogenetics / Q000379:methods* / Q000592:standards; D003955:Diagnostic Tests, Routine / Q000191:economics / Q000379:methods / Q000592:standards; D005260:Female; D005467:Floxuridine / Q000494:pharmacology; D005492:Folic Acid / Q000008:administration & dosage; D005600:Fragile X Syndrome / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D005820:Genetic Testing; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007621:Karyotyping; D008214:Lymphocytes / Q000187:drug effects / Q000648:ultrastructure*; D008297:Male; D008677:Metaphase; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D011785:Quality Assurance, Health Care; D012189:Retrospective Studies; D013936:Thymidine / Q000494:pharmacology
chemical_list: D003470:Culture Media; D005467:Floxuridine; D005492:Folic Acid; D013936:Thymidine